翰森製藥2024財報:總收入超122億元,溢利大漲33%達43.72億元
今日,翰森製藥發佈2024年業績報告,報告期內,公司實現總收入約122.61億元人民幣(單位下同),同比增長約21.3%;溢利約43.72億元,同比增長約33.4%;每股基本盈利約0.74元,同比增長約33.3%,每股派息13.53港仙。報告期內,公司創新藥與合作產品銷售收入94.77億元,同比增長38.1%,佔總收入比例上升至約77.3%;研發開支27.02億元,同比增長28.8%,佔總收入比例約22.0%。公司持續專注腫瘤、中樞神經系統、代謝、自免等疾病領域,正在推進超60項創新藥臨牀試驗,分屬40個候選創新藥,多個重點產品取得關鍵進展。2024年,翰森製藥達成多項許可引入合作,並將自研臨牀前口服小分子GLP-1藥物授予默沙東全球獨家許可權,交易首付款1.12 億美元,里程碑付款最高可達19億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.